In the HR-negative subpopulation ( n = @ ) , median progression-free survival with everolimus was @ months ( @ % CI @-@ ) versus @ months ( @-@ ) with placebo ( hazard ratio @ , @ % CI @-@ ; p = @ ) ; however , the protocol-specified significance threshold ( p = @ ) was not crossed .